A significant leap in maternal-fetal medicine was announced yesterday, as a Yale-born innovation moves toward global commercialization to address some of the most persistent challenges in obstetrics. Wavelet Medical, a spinout from Yale University, has partnered with Aegis Ventures to develop the first AI-powered non-invasive fetal EEG monitoring platform, a technology designed to detect fetal brain distress in real time.
The partnership, backed by $7 million in seed funding, aims to fundamentally redefine the standard of care for pregnant persons and their babies. By shifting the focus from indirect markers of fetal health to direct neurological measurement, the technology seeks to eliminate preventable brain injuries at birth and reduce the frequency of unnecessary caesarean sections.
For decades, the primary tool for monitoring fetal well-being during labor has been fetal heart rate monitoring (FHM). Whereas widely used, FHM does not directly measure the brain’s function. According to data released by the partnership, FHM is indeterminate in up to 85% of births, creating a precarious gap in care. This lack of precision often leads to two critical failures: missed cases of hypoxia that result in lifelong disability for the infant, or false positives that drive unnecessary surgical interventions for the mother.
Wavelet Medical intends to change this paradigm by measuring the organ that provides the only definitive neurological status: the brain. This approach represents a shift toward a more precise, data-driven method of assessing fetal distress, potentially sparing thousands of families from avoidable trauma.
Bridging the Gap: From Heart Rate to Brain Activity
The core of the innovation lies in the ability to capture electroencephalography (EEG) signals non-invasively. Traditionally, fetal EEG required invasive scalp electrodes, which introduced risks to both the mother and the baby and were impractical for routine clinical use. Wavelet’s platform captures EEG signals through the mother’s abdomen, removing the need for invasive procedures.
The technical breakthrough is powered by proprietary AI algorithms engineered by Dr. Jose Cortes-Briones, Wavelet’s Head of Science. Since signals captured through the maternal abdomen are complex and noisy, AI is required to reconstruct the fetal EEG and translate it into quantitative markers of distress. Specifically, the platform identifies auditory-evoked brain responses, which serve as critical indicators of whether the fetal brain is functioning normally or experiencing neurological distress.
Dr. Cortes-Briones noted that until recently, non-invasive fetal EEG from the maternal abdomen was not feasible, but the integration of AI now allows for the reconstruction of these signals to provide actionable medical data.
The Public Health Impact of Fetal Neurological Monitoring
The scale of the problem this technology addresses is substantial. In the United States alone, more than 35,000 infants suffer brain injuries at birth each year . These injuries often stem from hypoxia—a lack of oxygen to the brain—which may go undetected by standard heart rate monitors until We see too late to intervene effectively.
Simultaneously, the reliance on indeterminate heart rate data contributes to a high rate of surgical births. Approximately one-third of all births in the U.S. Are delivered via caesarean section. While C-sections are life-saving when necessary, unnecessary surgeries increase maternal morbidity and prolong recovery times. By providing a direct measure of neurological function, the Wavelet platform could help clinicians distinguish between a fetus that is simply reacting to labor and one that is in genuine neurological distress.
Key Comparison: Fetal Heart Rate Monitoring vs. AI-EEG
| Feature | Fetal Heart Rate Monitoring (FHM) | Wavelet AI-EEG Platform |
|---|---|---|
| Measurement Target | Cardiac activity (Indirect) | Brain activity (Direct) |
| Precision | Indeterminate in up to 85% of births | Quantitative markers of neurological status |
| Method | Standard external/internal sensors | Non-invasive abdominal capture + AI reconstruction |
| Primary Risk | Missed hypoxia or false positives | Aims to reduce preventable brain injury and unnecessary C-sections |
Leadership and the Path to Commercialization
Wavelet Medical is led by a multidisciplinary team combining clinical expertise and scientific innovation. The company was founded by CEO Liz Golden, Chief Medical Officer Dr. Emily Lee, and Dr. Jose Cortes-Briones. Their mission is to move this breakthrough from a laboratory discovery at Yale into a scalable, global commercial product.
The $7 million in seed funding provided by Aegis Ventures is intended to co-create and scale the platform, ensuring that the AI-powered monitoring can be integrated into existing obstetric workflows. The focus will be on refining the AI’s ability to provide real-time alerts to clinicians, allowing for immediate intervention when brain distress is detected.
As a physician, I discover the move toward “quantitative markers” particularly promising. In internal medicine and public health, we have seen how moving from subjective observation to objective, data-backed diagnostics saves lives. Applying this logic to the fetal environment—where the patient cannot communicate and the monitoring is traditionally indirect—could significantly lower the rate of neonatal disability.
The next phase for Wavelet Medical involves the transition from laboratory validation to clinical scaling. While the technology promises a new standard of care, the focus will now shift toward demonstrating its efficacy in diverse clinical settings to ensure that the AI algorithms perform consistently across different maternal profiles.
We will continue to monitor the progress of this platform as it moves through the commercialization process. Please share your thoughts on this innovation in the comments below or share this article with colleagues in the healthcare community.